Tokyo, October 30, 2017 - Nippon Boehringer Ingelheim Co., Ltd. (President and Representative Director: Yoshiaki Aono, 'Nippon Boehringer Ingelheim') and Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka, 'Astellas' ) announced today that they have agreed to extend the agreement pertaining to the sales of telmisartan (Micardis family) in Japan to March 31, 2020. The co-promotion agreement will run to March 31, 2018, with no change.

The Micardis family includes 'Micardis Tablets 20 mg/40 mg/80 mg', a long-acting angiotensin II receptor antagonist (generic name: telmisartan), 'Micamlo Combination Tablets AP/BP', a combination drug of telmisartan and the long-acting calcium channel blocker amlodipine besylate, Micombi Combination Tablets AP/BP, a combination drug of telmisartan and the thiazide diuretic hydrochlorothiazide, and Micatrio Combination Tablets', a combination drug of telmisartan, the long-acting calcium channel blocker amlodipine besylate and the thiazide diuretic hydrochlorazide.

The revision of the agreement will have no impact on financial results for the current fiscal year ending March 31, 2018.

Astellas Pharma Inc. published this content on 30 October 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 30 October 2017 01:07:04 UTC.

Original documenthttps://www.astellas.com/en/corporate/news/detail/extension-of-agreement-pertain.html

Public permalinkhttp://www.publicnow.com/view/C14A46D008FEC56A00E51F6CBD20A5E36DA0EE77